Abstract
Background: This review aims to conduct a comprehensive and systematic report of the currently published information on the association between elevated hepcidin levels and the risk of preeclampsia by meta-analysis of published prospective case-control studies or cross-sectional studies combined with follow-up to provide a comprehensive and reliable basis for early intervention and clinical decision making in the disease.
Methods: We searched five databases such as Pubmed, Web of Science, Cochrane, China National Knowledge Infrastructure, and WAN FANG DATA to retrieve articles related to the relationship between elevated levels of hepcidin and the risk of preeclampsia up to February 2025. We calculated the standardized mean deviation (SMD) and 95% confidence interval (95% CI) for comparison using a random-effects model.
Results: A total of 8 articles were included in this review. The results found that higher serum hepcidin and serum iron levels and lower serum transferrin levels were observed in pregnant women presenting with preeclampsia compared with normotensive pregnant women (serum hepcidin: SMD = 1.08, 95%CI: 0.03, 2.14; serum iron: SMD = 0.63, 95%CI: 0.41, 0.86; serum transferrin: SMD = -0.50, 95%CI: -0.73, -0.27).
Conclusions: Similar to the previous review, this systematic review and meta-analysis showed that high serum iron levels might be associated with a higher risk for preeclampsia. In addition, this meta-analysis summarized two mechanisms for the failure of hepcidins to reduce serum iron levels in pregnant mothers with preeclampsia in late pregnancy. And this meta-analysis would guide further clinical studies.
Keywords
Array
Array
Array
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.